CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancers.
  
  LEARNING OBJECTIVES

  • Assess the biologic rationale for combining an immune checkpoint inhibitor with an anti-angiogenic agent in the management of hepatocellular carcinoma (HCC).
  • Evaluate Phase III data leading to the recent FDA approval of atezolizumab in combination with bevacizumab for patients with unresectable or metastatic HCC who have not received prior systemic therapy.
  • Discuss available Phase III data supporting the FDA approval of lenvatinib as first-line therapy for patients with unresectable HCC, and discern how this agent can be optimally integrated into clinical care.
  • Individualize the selection of systemic therapy for newly diagnosed and relapsed or refractory HCC, considering clinical presentation, liver function, coexisting medical conditions and patient preferences.
  • Develop an evidence-based approach to the selection and sequencing of available therapeutic options for patients with HCC.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with targeted agents and immunotherapeutic approaches in the management of HCC.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC, and where applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Richard S Finn, MD
  Professor, Department of Medicine, Division of Hematology/Oncology
  David Geffen School of Medicine at UCLA
  Director, Signal Transduction and Therapeutics Program
  Jonsson Comprehensive Cancer Center at UCLA
  Los Angeles, California
  
  Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CStone Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Tim Greten, MD
  Bethesda, Maryland
  
  No financial interests or affiliations to disclose.
  
  James J Harding, MD
  Assistant Attending
  Gastrointestinal Oncology Service
  Early Drug Development Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Imvax, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: Merck.
  
  Ahmed Omar Kaseb, MD, CMQ
  Professor and Director, Hepatocellular Carcinoma Program
  Co-Director, MD Anderson HCC SPORE
  Editor-in-Chief, Journal of Hepatocellular Carcinoma
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group; Contracted Research: Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, and Merck.
  
  Release date: March 2021
  Expiration date: March 2022